tiprankstipranks
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
Hong Kong Market
1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
RESEARCH TOOLSreports

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Ratios

3 Followers

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Ratios

HK:1541's free cash flow for Q2 2025 was ¥1.00. For the 2025 fiscal year, HK:1541's free cash flow was decreased by ¥ and operating cash flow was ¥-3.44. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
 3.83 4.04 5.92 12.60
Quick Ratio
 3.83 3.93 5.92 12.42
Cash Ratio
 2.47 2.23 2.65 12.28
Solvency Ratio
 -0.67 -1.25 -2.83 -6.34
Operating Cash Flow Ratio
 -0.49 -0.60 -3.17 -4.61
Short-Term Operating Cash Flow Coverage
 -0.70 -1.27 -6.13 0.00
Net Current Asset Value
¥ 748.76M¥ 624.25M¥ 560.40M¥ 591.11M
Leverage Ratios
Debt-to-Assets Ratio
 0.21 0.15 0.09 0.02
Debt-to-Equity Ratio
 0.29 0.20 0.10 0.02
Debt-to-Capital Ratio
 0.22 0.17 0.09 0.02
Long-Term Debt-to-Capital Ratio
 0.03 0.02 0.00 0.00
Financial Leverage Ratio
 1.39 1.36 1.17 1.08
Debt Service Coverage Ratio
 -1.03 -2.83 -5.78 -488.55
Interest Coverage Ratio
 -77.28 -89.31 -239.29 -463.09
Debt to Market Cap
 0.13 0.06 <0.01 0.00
Interest Debt Per Share
 0.54 0.37 0.21 0.04
Net Debt to EBITDA
 2.22 1.15 0.65 1.61
Profitability Margins
Gross Profit Margin
85.25%100.00%1993.52%100.00%
EBIT Margin
-137.21%-415.44%-97910.62%-7066.91%
EBITDA Margin
-128.50%-398.70%-92060.10%-6757.29%
Operating Profit Margin
-137.21%-415.44%-94474.87%-6405.13%
Pretax Profit Margin
-137.77%-426.96%-98305.44%-7080.74%
Net Profit Margin
-137.35%-425.97%-98305.44%-7080.74%
Continuous Operations Profit Margin
-137.79%-426.96%-98305.44%-7080.74%
Net Income Per EBT
99.69%99.77%100.00%100.00%
EBT Per EBIT
100.41%102.77%104.05%110.55%
Return on Assets (ROA)
-19.79%-34.26%-43.39%-47.96%
Return on Equity (ROE)
-32.79%-46.52%-50.71%-51.70%
Return on Capital Employed (ROCE)
-26.10%-43.55%-48.07%-46.24%
Return on Invested Capital (ROIC)
-21.09%-37.81%-44.31%-45.91%
Return on Tangible Assets
-19.79%-34.26%-47.50%-53.01%
Earnings Yield
-11.61%-17.28%-3.87%-6.26%
Efficiency Ratios
Receivables Turnover
 11.18 402.98 9.90 86.21
Payables Turnover
 0.00 0.00 >-0.01 0.00
Inventory Turnover
 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 4.72 1.55 <0.01 0.03
Asset Turnover
 0.14 0.08 <0.01 <0.01
Working Capital Turnover Ratio
 0.25 0.12 <0.01 >-0.01
Cash Conversion Cycle
 32.63 0.91 102.06K 4.23
Days of Sales Outstanding
 32.63 0.91 36.88 4.23
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 0.00 0.00 -102.02K 0.00
Operating Cycle
 32.63 0.91 36.88 4.23
Cash Flow Ratios
Operating Cash Flow Per Share
 -0.32 -0.34 -1.02 -0.64
Free Cash Flow Per Share
 -0.33 -0.37 -1.02 -0.70
CapEx Per Share
 0.01 0.03 <0.01 0.06
Free Cash Flow to Operating Cash Flow
 1.03 1.08 1.01 1.10
Dividend Paid and CapEx Coverage Ratio
 -28.64 -12.31 -136.59 -10.28
Capital Expenditure Coverage Ratio
 -28.64 -12.31 -136.59 -10.28
Operating Cash Flow Coverage Ratio
 -0.60 -0.94 -4.92 -16.33
Operating Cash Flow to Sales Ratio
 -0.86 -1.73 -952.21 -41.95
Free Cash Flow Yield
-7.60%-7.57%-3.78%-4.07%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -8.11 -5.79 -25.83 -15.97
Price-to-Sales (P/S) Ratio
 11.03 24.65 25.39K 1.13K
Price-to-Book (P/B) Ratio
 2.23 2.69 13.10 8.26
Price-to-Free Cash Flow (P/FCF) Ratio
 -12.40 -13.20 -26.48 -24.56
Price-to-Operating Cash Flow Ratio
 -12.96 -14.28 -26.67 -26.95
Price-to-Earnings Growth (PEG) Ratio
 -0.25 0.29 9.30 0.36
Price-to-Fair Value
 2.23 2.69 13.10 8.26
Enterprise Value Multiple
 -6.37 -5.03 -26.93 -15.12
Enterprise Value
 1.40B 1.49B 9.57B 5.81B
EV to EBITDA
 -6.89 -5.03 -26.93 -15.12
EV to Sales
 8.86 20.05 24.79K 1.02K
EV to Free Cash Flow
 -9.95 -10.74 -25.85 -22.19
EV to Operating Cash Flow
 -10.30 -11.61 -26.04 -24.35
Tangible Book Value Per Share
 1.86 1.80 1.86 1.87
Shareholders’ Equity Per Share
 1.86 1.80 2.07 2.09
Tax and Other Ratios
Effective Tax Rate
 >-0.01 0.00 0.00 0.00
Revenue Per Share
 0.37 0.20 <0.01 0.02
Net Income Per Share
 -0.51 -0.84 -1.05 -1.08
Tax Burden
 1.00 1.00 1.00 1.00
Interest Burden
 1.00 1.03 1.00 1.00
Research & Development to Revenue
 1.98 4.35 756.33 48.74
SG&A to Revenue
 0.24 0.87 208.35 16.31
Stock-Based Compensation to Revenue
 0.16 0.46 185.60 18.25
Income Quality
 0.45 0.40 0.97 0.59
Currency in CNY